'''Tegaserod''' is a [[serotonin|5-HT]]<sub>4</sub> [[agonist]] manufactured by [[Novartis]] and sold under the names '''Zelnorm''' and '''Zelmac''' for the management of [[irritable bowel syndrome]] and [[constipation]].<ref>{{cite web|url=http://www.pharma.us.novartis.com/newsroom/pressReleases/releaseDetail.jsp?PRID=2004 |title= New Data for Zelnorm |accessdate= March 30, 2007}}</ref> Approved by the FDA in 2002, it was subsequently removed from the market in 2007 due to FDA concerns about possible adverse cardiovascular effects.  Before then, it was the only drug approved by the [[United States of America|United States]] [[Food and Drug Administration]] to help relieve the [[abdomen|abdominal]] discomfort, [[bloating]], and constipation associated with irritable bowel syndrome.  Its use was also approved to treat chronic [[idiopathic]] constipation.<ref>{{cite web|url=http://www.fda.gov/bbs/topics/ANSWERS/2002/ANS01160.html |title=FDA approves first treatment for women with irritable-bowel syndrome |accessdate= March 30, 2007 |archiveurl = https://web.archive.org/web/20070205163603/http://www.fda.gov/bbs/topics/ANSWERS/2002/ANS01160.html <!-- Bot retrieved archive --> |archivedate = February 5, 2007}}</ref>

 
The drug functions as a [[motility]] stimulant, achieving its desired therapeutic effects through activation of the 5-HT<sub>4</sub> receptors of the [[enteric nervous system]] in the [[Human gastrointestinal tract|gastrointestinal tract]]. It also stimulates gastrointestinal motility and the [[peristalsis|peristaltic]] reflex, and allegedly reduces abdominal pain.<ref>{{cite book |last=Rossi |first=S. |title=Australian Medicines Handbook |year=2004 |publisher=Health Communication Network |location=Adelaide |isbn=0-9578521-4-2 }}</ref> Additionally, tegaserod is a [[5-HT2B receptor|5-HT<sub>2B</sub> receptor]] antagonist.<ref name="pmid15466450">{{cite journal  |vauthors=Beattie DT, Smith JA, Marquess D, etal |title=The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo |journal=Br. J. Pharmacol. |volume=143 |issue=5 |pages=549â€“60 |date=November 2004 |pmid=15466450 |pmc=1575425 |doi=10.1038/sj.bjp.0705929}}</ref>
